Ferric Pyrophosphate Citrate

Summary

Ferric Pyrophosphate Citrate (CHEMBL3833317) is an approved small molecule; indicated across 3 conditions including chronic kidney disease and iron deficiency anemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833317
Name	Ferric Pyrophosphate Citrate
Type	Small molecule
Max phase	4

Also known as: Ferric pyrophosphate citrate, H-61, H61, SFP, Triferic avnu, Triferic, FERRIC PYROPHOSPHATE CITRATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic kidney disease	4	MONDO:0005300	EFO:0003884
iron deficiency anemia	2	MONDO:0001356	HP:0001891
kidney failure	1	MONDO:0001106	EFO:1002048

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE1/PHASE2	4
PHASE1	4
PHASE3	2
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04689932	PHASE4	COMPLETED	Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
NCT01503021	PHASE3	COMPLETED	Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis
NCT04239391	PHASE3	UNKNOWN	Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
NCT02595437	PHASE1/PHASE2	COMPLETED	Triferic Pediatric Pharmacokinetic Protocol
NCT02905981	PHASE2	TERMINATED	Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol
NCT03303144	PHASE1/PHASE2	COMPLETED	Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
NCT04042324	PHASE1/PHASE2	COMPLETED	A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
NCT04409132	PHASE1/PHASE2	COMPLETED	Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.
NCT05110768	PHASE2	UNKNOWN	Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy
NCT02636049	PHASE1	COMPLETED	Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers
NCT02739100	PHASE1	COMPLETED	Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
NCT02767128	PHASE1	COMPLETED	Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl’s Solution in Healthy Volunteers
NCT02909153	PHASE1	COMPLETED	Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).